Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.60 |
| ▸ | ACP1 | P24666 | 1/20 | 0.54 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.54 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.54 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.54 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.54 |
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | MAX | P61244 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277354 | 1.00 | TACR1 (0.60) | TACR1ACP1PTPN7PTPN12PTPN13 | |
| SCHEMBL21880132 | 0.90 | MEN1 (0.59) | POLBMAPT | |
| SCHEMBL21880131 | 0.90 | MEN1 (0.59) | POLBMAPT | |
| SCHEMBL21880198 | 0.88 | MAPT (0.65) | TP53POLBMAPTBACE1AKT1 | |
| SCHEMBL21880197 | 0.88 | MAPT (0.65) | TP53POLBMAPTBACE1AKT1 | |
| SCHEMBL11306381 | 0.86 | TACR1 (0.63) | TACR1ACP1PTPN7PTPN12PTPN13 | |
| SCHEMBL30454484 | 0.82 | BACE1 (0.52) | BACE1AKT1ALPIPKMPTGS1 | |
| SCHEMBL5019067 | 0.82 | ALDH1A1 (0.53) | TP53POLBMAPTPKMLMNA | |
| SCHEMBL2312372 | 0.81 | BACE1 (0.63) | BACE1AKT1ALPIPKMPTGS1 | |
| SCHEMBL2312361 | 0.81 | BACE1 (0.63) | BACE1AKT1ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021151104-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-29 | — | — | WO | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | TACR1 4852/4885ACP1 360/4885PTPN7 701/4885 |
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | EIF2AK2, SARS1, ACE | TACR1 4370/4885ACP1 3867/4885PTPN7 3665/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | TACR1 1746/4885ACP1 1790/4885PTPN7 1788/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | TACR1 1398/4885ACP1 2814/4885PTPN7 3657/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | TACR1 1407/4885ACP1 2881/4885PTPN7 3557/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | TACR1 2677/4885ACP1 147/4885PTPN7 430/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | TACR1 1540/4885ACP1 2683/4885PTPN7 3258/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | TACR1 1524/4885ACP1 2680/4885PTPN7 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.